MARKET

SBBP

SBBP

Strongbridge
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.990
-0.130
-6.13%
After Hours: 2.000 +0.01 +0.50% 16:28 09/20 EDT
OPEN
2.080
PREV CLOSE
2.120
HIGH
2.110
LOW
1.980
VOLUME
180.48K
TURNOVER
--
52 WEEK HIGH
4.260
52 WEEK LOW
1.850
MARKET CAP
134.98M
P/E (TTM)
-3.2893
1D
5D
1M
3M
1Y
5Y
Xeris Pharmaceuticals Shareholders Approve Pending Strongbridge Biopharma Acquisition
MT Newswires · 5d ago
BRIEF-Xeris Pharmaceuticals Stockholders Approve Acquisition Of Strongbridge Biopharma
reuters.com · 6d ago
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) ("Xeris") today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) ("Strongbridge") by Xeris.
Business Wire · 6d ago
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Benzinga · 09/09 12:17
BRIEF-Strongbridge Biopharma Announces Shareholder Approval Of Proposed Acquisition By Xeris Pharmaceutical
reuters.com · 09/08 20:14
BRIEF-Glass Lewis Recommends Strongbridge Shareholders Vote "For" Xeris Deal
reuters.com · 08/31 11:34
BRIEF-ISS Recommends Strongbridge Biopharma Shareholders Vote "For" Xeris Deal
reuters.com · 08/30 11:45
BRIEF-Iss Recommends Strongbridge Biopharma PLC Shareholders Vote "For" Transaction With Xeris
reuters.com · 08/30 11:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SBBP. Analyze the recent business situations of Strongbridge through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SBBP stock price target is 5.00 with a high estimate of 8.00 and a low estimate of 3.250.
EPS
Institutional Holdings
Institutions: 89
Institutional Holdings: 35.83M
% Owned: 52.83%
Shares Outstanding: 67.83M
TypeInstitutionsShares
Increased
12
3.95M
New
19
8.91M
Decreased
24
5.02M
Sold Out
33
6.77M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.35%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
President/Chief Financial Officer
Richard Kollender
Chief Executive Officer
John Johnson
Other
Frederic Cohen
Other
Scott Wilhoit
Secretary
Stephen Long
Lead Director/Independent Director
Garheng Kong
Independent Director
David Gill
Independent Director
Jeffrey Sherman
Independent Director
Marten Steen
Independent Director
Hilde Steineger
No Data
About SBBP
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Webull offers kinds of Strongbridge Biopharma plc stock information, including NASDAQ:SBBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SBBP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SBBP stock methods without spending real money on the virtual paper trading platform.